Seagen Valuation
Is SGEN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SGEN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SGEN * (MX$3711.48) is trading above our estimate of fair value (MX$3007.4)
Significantly Below Fair Value: SGEN * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SGEN *?
Key metric: As SGEN * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SGEN *'s PS Ratio? | |
|---|---|
| PS Ratio | 17.5x |
| Sales | US$2.06b |
| Market Cap | US$35.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 16.8x |
| Enterprise Value/EBITDA | -58.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SGEN *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.3x | ||
A068270 Celltrion | 12.4x | 25.4% | ₩35.8t |
HZNP Horizon Therapeutics | 7.3x | 8.3% | US$26.6b |
BIIB Biogen | 2.4x | 1.3% | US$22.7b |
ALNY Alnylam Pharmaceuticals | 15.2x | 22.4% | US$32.1b |
SGEN * Seagen | 17.5x | 23.1% | Mex$35.9b |
Price-To-Sales vs Peers: SGEN * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the peer average (7.4x).
Price to Sales Ratio vs Industry
How does SGEN *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 281 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 281 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: SGEN * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is SGEN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 17.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SGEN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
ICON
US$16.8b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
IQVIA Holdings
US$35.9b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%